{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-051168","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.221843+00:00","generated_at":"2026-05-16T22:18:49.055365+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Precision BioSciences reports positive Phase 1 PBGENE-HBV data; first human biopsy evidence of viral gene editing","bullets":["Phase 1 ELIMINATE-B trial: 9 patients across 0.2, 0.4, 0.8 mg/kg doses (22 total administrations); no dose-limiting toxicities observed.","All patients showed HBsAg reductions; Cohort 3 (0.8 mg/kg) had steep early declines with cumulative effect – one patient achieved 64% decrease.","Paired liver biopsy from Cohort 2 confirmed ARCUS-mediated indel edits in HBV DNA – first direct human evidence of viral gene editing.","Transient infusion reactions and asymptomatic platelet fluctuations; one reversible Grade 3 AST elevation resolved within 3 days.","Cohort 3 dosing to complete Q1 2026; next step: Part 2 expansion with optimized regimen and mandatory paired biopsies."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-051168","json":"https://secwatch.observer/filing/0001628280-25-051168.json","markdown":"https://secwatch.observer/filing/0001628280-25-051168.md","text":"https://secwatch.observer/filing/0001628280-25-051168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828025051168/0001628280-25-051168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828025051168/dtil-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:18:49.055365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}